Drugs / T-cell depleted HPC transplant
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02259348 | Oct 2014 → Apr 2015 | acute lymphoblastic leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome +1 | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-cell depleted HPC transplant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02259348 ↗ |
| Modality | Cell therapy | “T-cell depleted hematopoietic stem cells will be infused on day 0.” NCT02259348 ↗ |
| Route | Intravenous | “later infused (transplanted) into the participant through his/her veins” NCT02259348 ↗ |